James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information
Advertisements

Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Percutaneous mitral valve repair using the MitraClip® device (e-valve)
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /
Percutaneous Repair or Surgery for Mitral Regurgitation EVEREST II Objective:to compare the efficacy of percutaneous implantation of a clip and conventional.
Disclosure Statement of Financial Interest Saibal Kar, MD, FACC
MitraClip Mitral Valve Repair System Rachel McAteer BME 181.
A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Treatment of Chronic Functional Mitral Valve Regurgitation.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Extending the Boundaries of TAVR: Future Directions
Transcatheter Mitral Valve Replacement
Role of Device Therapy in FMR: Challenges and Opportunities
From Mitral Repair to Replacement
Minimally Invasive Mitral Valve Repair
Figure 1 Changes of mitral valve geometry caused by PMVR
Volume 69, Issue 2, Pages (February 2017)
CTSN Trials of Mitral Valve Repair and Replacement
on behalf of the EVEREST Investigators
Cardiovacular Research Technologies
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
Division of Cardiac Surgery University of Ottawa Heart Institute
University of Pennsylvania Philadelphia
Functional MR: When to Intervene
Updates From NOTION: The First All-Comer TAVR Trial
Mitralign Program Update
The CARILLON: Device Iteration, New Data and New Trials
Case Demonstration: MitraClip Edge-to–Edge Repair
The Spectrum of Evolving Mitral Repair Techniques
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Washington Hospital Center
Thierry MESANA, MD, PhD President and CEO Professor Cardiac Surgery
How I treat Functional Mitral Regurgitation: The Surgeon’s perspective
Early Feasibility Studies Investigator Perspective
Surgical Mitral Valve Repair: What is the Gold Standard?
EVEREST II 5-Year Report and Beyond
Debate - EVEREST and Residual Mitral Regurgitation: Percutaneous Mitral Devices Will Change the Indications for Mitral Valve Procedures Niv Ad, MD Chief,
Timing of Intervention in Mitral Stenosis
Dynamic Mitral Valve Ring Annuloplasty: Micardia Concept
Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
MitraClip: A Therapeutic Solution for Patients with Severe MR – Not a Candidate for Surgery Brij Maini MD, FACC Regional Medical Director of Transcatheter.
Risk Stratification of Severe, Symptomatic Aortic Stenosis Patients
Cardiovacular Research Technologies
Nishith Patel Waikato Cardiothoracic Unit
Ischemic Mitral Regurgitation
A heart team’s perspective on interventional mitral valve repair: Percutaneous clip implantation as an important adjunct to a surgical mitral valve program.
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Benefits of Early Surgery on Clinical Outcomes After Degenerative Mitral Valve Repair  Tianyu Zhou, MD, Jun Li, MD, PhD, Hao Lai, MD, PhD, Kai Zhu, MD,
A “Repair-All” Strategy for Degenerative Mitral Valve Disease Safely Minimizes Unnecessary Replacement  Andrew B. Goldstone, MD, Jeffrey E. Cohen, MD,
Baseline left ventricular function and surgical annular stiffening to predict outcome and reverse left ventricular remodeling after undersized annuloplasty.
Quick but effective surgery for functional mitral regurgitation secondary to aortic valve disease  Masashi Komeda, MD, PhD  The Journal of Thoracic and.
Jorge Sierra, MD, FETCS, Nadia H. Lahlaïdi, MD, Jan T
Percutaneous edge-to-edge repair in high-risk and elderly patients with degenerative mitral regurgitation: Midterm outcomes in a single-center experience 
Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial  Michael A. Acker, MD,
Very long-term results (up to 17 years) with the double-orifice mitral valve repair combined with ring annuloplasty for degenerative mitral regurgitation 
Tirone E. David, MD, Carolyn M. David, BN, Cedric Manlhiot, MS 
(A): Five-year mortality in unoperated patients with severe MR with E/E′≥15 was significantly higher compared with patients with E/E′
Rick A. Nishimura et al. JACC 2017;70:
Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience  Tirone E. David, MD, Susan Armstrong, MSc, Joan.
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN Structural Heart & Valve FDA Workshop - February 22, 2010 Debate #5 The Enemy of Good is Better?: Percutaneous Mitral Valve Procedures Don’t Have to Match Open Surgical Results James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN

Disclosure Information The following relationship exists: Grant support: Evalve EVEREST Studies Consultant for Abbott

Euro Heart Survey: Surgery is often denied in the older patients Isolated MR (n=877) Severe MR (n=546) No Severe MR (n=331) 2/3 of symptomatic MR patients >70 are denied surgery Symptoms (n=396) No Symptoms (n=144) No Intervention (n=193) 49% Intervention (n=203) 51% Mirabel et al, European Heart J 2007;28:1358-1365 3

Surgery vs Percutaneous Repair Large group of patients who have severe mitral regurgitation who surgical correction is not an option (or not offered) In these non-surgical patients clearly percutaneous mitral valve procedures don’t have to match open surgical results; compare to medical therapy/CRT alone

Euro Heart Survey: Isolated MR (n=877) Severe MR No Severe MR (n=546) Symptoms (n=396) No Symptoms (n=144) No Intervention (n=193) 49% Intervention (n=203) 51% Mirabel et al, European Heart J 2007;28:1358-1365 8

EFFICACY INVASIVENESS Goal Traditional Less invasive surgery BAD Traditional surgery Less invasive Goal Percutaneous techniques EFFICACY INVASIVENESS 9

The Balance Percutaneous Repair Surgical Repair Less Invasive Lower Morbidity More Rapid Return to Function Surgical Repair Long Term Outcome Known Better Efficacy – Less MR and Durable

Surgery vs Percutaneous Repair The Efficacy Metric MR reduction by echocardiography Is zero/trivial MR better than 2+??? Symptom relief Mortality

MR Reduction and Remodeling LVEDVI and LVESVI (Indexed Volumes) MitraClip Therapy: Significant Reverse LV Remodeling P<.0001 P=.0007 89 74 36 31 Diastolic Systolic Baseline 12 Months 12 month matched data, n=47, MR≤2 at 12 months

EVEREST Preliminary FMR Cohort: NYHA Class 75% (9/12) Improved 17% (2/12) No Change 8% (1/12) Worsened w/o MR > 1+ Freedom from NYHA Class III or IV from 25% to 75%” Patients included in the Matched Pair Analysis at 12-m: 01-0003, 03-0002, 03-0003, 03-0010, 04-0002, 04-0701, 17-501, 18-502, 19-501, 21-501, 23-501, 25-501

Is a Ticket Burned? Are Surgical Options Preserved?

Flow chart :Outcomes of patients who had surgery after a clip attempt. Mitral valve (MV) repair with the use of a surgical approach to create a double-orifice valve was first performed by Alfieri in 1991 (Fig. 1) (1–3). Durable results in surgically-treated patients without annuloplasty have been described in selected patients for as long as 12 years after surgical repair (4,5). Percutaneous mitral repair based on this surgical technique has been developed by the use of a clip rather than suture to secure the mitral leaflets (6,7). The Feldman et al. JACC, 2009:686–94

If a Bridge Isn’t Burned – Any Harm in Delaying/Avoiding Surgical Intervention?

Recurrence of Mitral Valve Regurgitation After Mitral Valve Repair in Degenerative Valve Disease Willem Flameng, MD, PhD; Paul Herijgers, MD, PhD; Kris Bogaerts, MSc Freedom from severe MR (>2/4) was 18% at 5 yrs and 29% at 7 yrs Circulation. 2003;107:1609-1613.

Conclusions Large group of patients not offered surgical option – in these (at least half) percutaneous repair clearly does not have to match surgical results In those with a surgical option, less procedural morbidity/mortality, more rapid return to function, preservation of surgical options, and limitations of surgical repair, suggests that percutaneous mitral valve procedures don’t have to match open surgical results